Post by Clinical Pharmacology MedUni Vienna

How do we determine whether an antibiotic actually reaches the site where it is needed? For bacterial prostatitis, this is a fundamental question. An antibiotic may show excellent activity against pathogens in the laboratory, but its clinical potential also depends on whether sufficient concentrations reach the prostate tissue. In our latest publication in "Clinical Microbiology and Infection", we investigated the tissue distribution of gepotidacin, a novel antibacterial agent, using an ex vivo microdialysis approach combined with population pharmacokinetic modelling. Our findings show that unbound gepotidacin concentrations in prostate tissue were comparable to those in plasma - an important prerequisite for evaluating its potential in this indication. At the same time, the study illustrates how much work remains to be done. Understanding tissue exposure is only one step towards defining pharmacokinetic/pharmacodynamic targets and, ultimately, improving treatment strategies for bacterial prostatitis. This work was mad possible through close collaboration of clinicians, clinical pharmacologists, pharmacometricians, microbiologists and our partners across several institutions and countries. Our sincere thanks go to all co-authors, collaborators and study participants for their dedication to this project. Scientific progress is rarely the result of a single experiment. It emerges through collaboration, methodological innovation and the careful accumulation of evidence. We hope this work contributes another piece to that broader picture. The publication is available as Open Access—we would be pleased to hear your thoughts and discuss its implications. https://lnkd.in/dQNXuf8h Authors: Valentin al Jalali ∙ Vincent Aranzana-Climent ∙ Anselm JORDA ∙ Felix Bergmann ∙ Edith Lackner ∙ Michael Wölfl-Duchek ∙ Amelie Leutzendorff1 ∙ Lena Pracher ∙ Lea Kum ∙ Maria Sanz Codina ∙ Stephan Korn ∙ Christian Seitz ∙ Gaëlle Fromont ∙ Shahrokh Shariat, MD ∙ Franck Bruyère ∙ Karen O’Dwyer ∙ Jeremy Dennison ∙ Hwa-Ping Feng ∙ Marchand Sandrine ∙ William Couet ∙ Markus Zeitlinger #ClinicalPharmacology #Pharmacokinetics #AntimicrobialResistance #InfectiousDiseases #Microdialysis #ClinicalResearch #Pharmacometrics #TranslationalResearch This project has received funding from the Innovative Health Initiative (IHI) Joint Undertaking (JU) under grant agreement No 853976. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA - European Federation of Pharmaceutical Industries and Associations. GSK provided funding for the bioanalysis of samples from this study.

Video Content